Patents Assigned to IMMUNO Aktiengesellschaft fur chemisch-medizinische Produkte
-
Patent number: 5385828Abstract: The invention refers to a method for determining the relative amounts of all cholesterol-containing lipoproteins in body fluids comprising electrophoretically separating the lipoproteins of an aliquot of body fluid on a thin layer carrier matrix, incubating the carrier matrix, containing the separated lipoproteins with cholesterol esterase and cholesterol dehydrogenase, forming a provable complex, and determining the relative amounts of the different lipoprotein classes2. The new method makes it possible to simultaneously determine HDL-, LDL-, VLDL- and LP (X)-cholesterol in body fluids with a high accuracy even at small concentrations. The thin layer matrices obtained electrophoretically, are very easy to handle and to record.Type: GrantFiled: November 24, 1992Date of Patent: January 31, 1995Assignee: "Immuno" Aktiengesellschaft fur chemisch-medizinische ProdukteInventor: Johannes Aufenanger
-
Patent number: 5324628Abstract: In order to avoid the risk of undesired side reactions of blood products, the latter are produced from plasma by using chymotrypsin to inactivate prekallikrein activator. These preparations are obtained by the fractionated enrichment of plasma proteins, with the proviso that a chymotrypsin solution or immobilized chymotrypsin is added to the fractions at any stage of the fractionation process. Before completion of the preparations, the chymotrypsin or the immobilized trypsin is removed from the preparations.Type: GrantFiled: October 15, 1991Date of Patent: June 28, 1994Assignee: Immuno Aktiengesellschaft Fur Chemisch-Medizinische ProdukteInventor: Yendra Linnau
-
Patent number: 5254532Abstract: A preparation for the treatment and prevention of thromboses and thromboembolic complications is disclosed, which preparation has a content of protein S at a concentration at least 50 times that present in native plasma and is free from C4b-binding protein, optionally in combination with a content of activated protein C.Type: GrantFiled: February 21, 1992Date of Patent: October 19, 1993Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Hans P. Schwarz, Ewald Molinari, Yendra Linnau, Susanne Pfeiler
-
Patent number: 5234685Abstract: There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating incompatibility-reaction-causing substances in blood products to be applied therapeutically and prophylactically. For this purpose, a fraction obtained from human or animal blood is treated with pancreas enzymes bound to water insoluble carrier material and, optionally, the fraction is subjected to further fractionation and concentration.Type: GrantFiled: September 26, 1989Date of Patent: August 10, 1993Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Johann Eibl, Yendra Linnau, Otto Schwarz
-
Patent number: 5094949Abstract: In order to avoid the risk of undesired side reactions of blood products, the latter are produced from plasma by using chymotrypsin to inactivate prekallikrein activator. These preparations are obtained by the fractionated enrichment of plasma proteins, with the proviso that a chymotrypsin solution or immobilized chymotrypsin is added to the fractions at any stage of the fractionation process. Before completion of the preparations, the chymotrypsin or the immobilized trypsin is removed from the preparations.Type: GrantFiled: February 24, 1989Date of Patent: March 10, 1992Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventor: Yendra Linnau
-
Patent number: 4946677Abstract: Preparations active against Pseudomonas aeruginosa Infections, namely vaccines for active immunization as well as preparations containing antibodies and destined for passive protection; as well as methods for the production thereof.The vaccines contain protective flagellar (H) antigens of the serotype a and b, which consist of monomeric components, each monomeric component is composed of certain amino acids having a certain N-terminal amino acid sequence and has a certain molecular weight. The vaccines are made from purified flagellar (H) antigen solutions. The immunoglobulin-G-containing preparations contain flagellar (H) antibodies obtained from the blood plasma of human donors or mammals immunized with protective flagellar (H) antigens. They can be purified by methods of affinity chromatography.Type: GrantFiled: June 17, 1987Date of Patent: August 7, 1990Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Friedrich Dorner, Johann Eibl
-
Patent number: 4909251Abstract: A tissue adhesive in lyophilized form contains at least one biologically compatible tenside beside fibrinogen and factor XIII and optionally further proteins as well as adjuvants or additives. The presence of these biologically compatible tensides was found to shorten the reconstitution times of lyophilized tissue adhesive preparations without negatively affecting the biochemical, mechanical or biological properties of the preparation or of the tibrin formed therefrom.Type: GrantFiled: May 31, 1989Date of Patent: March 20, 1990Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventor: Thomas Seelich
-
Patent number: 4904641Abstract: There is disclosed a method of inactivating reproducible filterable pathogens in blood plasma products by applying elevated temperatures. The blood plasma products are heat treated in a solid state in a closed inactivation container in the presence of specific amounts of water and organic compounds, provided that the water substantially remains physically bound to the blood plasma products, while the organic compound is present in a gaseous form in the atmosphere. The water content of the blood plasma products is 0.08 to 0.40. The concentration of the organic compounds in the gaseous phase is 0.01 to 10 g per liter of container volume.Type: GrantFiled: January 3, 1989Date of Patent: February 27, 1990Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Johann Eibl, Otto Schwarz, Fritz Elsinger, Gunter Wober, Anton Philapitsch, Yendra Linnau, Friedrich Dorner, Karl Trambauer, Wolfgang Frechinger
-
Patent number: 4886758Abstract: There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating incompatibility-reaction-causing substances in blood products to be applied therapeutically and prophylactically. For this purpose, a fraction obtained from human or animal blood is treated with pancreas enzymes bound to water insoluble carrier material and, optionally, the fraction is subjected to further fractionation and concentration.Type: GrantFiled: September 15, 1986Date of Patent: December 12, 1989Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Johann Eibl, Yendra Linnau, Otto Schwarz
-
Patent number: 4850373Abstract: A biopsy device including a two- or multi-lumen biopsy cannula has a biopsy channel of constant cross section over its entire length and at least one application channel. On its proximal end, it is provided with connection facilities for an aspiration device and at least one application device. In order to enable the collection of tissue specimens of an unchanged structure with the most careful handling possible of the tissue and the application of auxiliary substances into the puncture channel without tissue specimens getting into the application cannula and obstructing the same, the cutting edge is formed by an acute-angularly designed end of the biopsy channel wall alone. At least one application channel is formed by a tube eccentrically slipped over the biopsy channel wall. The biopsy channel wall projects out of the tube with its cutting edge and the tube end encloses an obtuse angle with the biopsy channel.Type: GrantFiled: March 25, 1988Date of Patent: July 25, 1989Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Kurt Zatloukal, Hans P. Dinges
-
Patent number: 4831121Abstract: Polydisperse native Pseudomonas flagellar (H) antigens (FAg) and methods of producing them are described, wherein each monomeric component contains certain amino acids, has a certain N-terminal amino acid sequence and a certain molecular weight and is free from pyrogenic substances. The ratio of the individual amino acids in the flagellar antigen of the individual H-serotypes is stated.For producing the polydisperse native Pseudomonas flagellar (H) antigens (FAg) methods are indicated, wherein Pseudomonas aeruginosa bacterial cultures or fractions thereof are treated with a detergent and the flagellar antigens are separated from the cultures. Prior to treatment or in the presence of the detergent, the bacterial culture is subjected to a shearing procedure, i.e. exposed to shearing forces. Thereafter, the flagellar antigens separated from the bacterial mass are isolated by a chromatographic treatment.Type: GrantFiled: October 2, 1986Date of Patent: May 16, 1989Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Thomas C. Montie, Friedrich Dorner, James L. McDonel, Artur Mitterer
-
Patent number: 4816251Abstract: There is disclosed a method of inactivating reproductive filterable pathogens in tissue adhesives containing fibrinogen and Factor XIII, with their biologic activity being largely preserved. In order to provide a tissue adhesive preparation of human or animal origin, which exhibits a high safety with respect to reproductive filterable pathogens and whose biologic activity is largely preserved, preparations having a minimum content of 100 units of Factor XIII/g of fibrinogen are heated in the dry state in the presence of an oxygen-free inert protective gas or under vacuum.Type: GrantFiled: September 13, 1985Date of Patent: March 28, 1989Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventor: Thomas Seelich
-
Patent number: 4814277Abstract: A method of inactivating reproductive filterable pathogens in immunoglobulin-G-containing blood fractions to be applied therapeutically or prophylactically. In order to preserve full activity of the blood products and to completely inactivate pathogenic viruses, an aqueous solution of an immunoglobulin-G-containing fraction obtained from human blood is treated with neutral hydrolases at a temperature of 4.degree. to 50.degree. C. and at a pH of 5.5 to 9.5.Type: GrantFiled: May 12, 1987Date of Patent: March 21, 1989Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Johann Eibl, Yendra Linnau
-
Patent number: 4735616Abstract: An arrangement for applying a tissue adhesive based on human or animal proteins, to seamlessly or seam-supportingly connect human or animal tissue or organ parts by uniting with blood-clot-promoting coagulation factors (thrombin). The arrangement includes a plurality of syringe bodies commonly actuatable by pistons and to which a connecting head is attachable. The syringe bodies have equal effective strokes, yet one of them, i.e., that destined to contain the protein solution, has a cross sectional area that is two to nine times larger than the other one(s). There may be applied tissue adhesives having a fibrinogen content of from 2 to 12%.Type: GrantFiled: June 17, 1986Date of Patent: April 5, 1988Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Johann Eibl, Thomas Seelich, Heinz Redl, Georg Habison
-
Patent number: 4687664Abstract: There is described a method of inactivating reproducible pathogens in preparations containing plasmatic enzymes and proenzymes, activated or non-activated coagulation factors, such as Factors II, V, VII, VIII, IX, X, XIII, "FEIBA", prothrombin complex preparations, plasmatic inhibitors, immunoglobulins or other blood products, such as fibronectin and fibrinogen. In order to break and overcome the protective effect of proteins on pathogens by simultaneously preserving the biological activity and the molecular integrity of the proteins, the preparation is adjusted to a salt concentration of more than 0.5 molar by the addition of ammonium sulfate and is thermally treated, whereupon the ammonium sulfate is removed from the preparation.Type: GrantFiled: April 30, 1984Date of Patent: August 18, 1987Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Anton Philapitsch, Gunter Wober, Johann Eibl, Otto Schwarz
-
Patent number: 4640834Abstract: A method of inactivating viruses in blood products is described, wherein the blood products are heat-treated in a humid or in a solid state in the presence of inorganic or organic hydroxyl group-containing compounds having an H.sup.+ -dissociation constant of <10.sup.-11 in a concentration of more than 0.05 (5% by weight) and less than 0.70 (70% by weight). The hydroxyl group-containing compounds may be water, methanol, ethanol or mannitol. The temperature may amount up to 121.degree. C., the heat treatment may last from 1 s to 100 h. The inactivation method may be applied for producing blood products selected from enzymes, proenzymes including coagulation factors, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin or plasma, the inactivation destroying any reproducible filterable pathogens that might be present.Type: GrantFiled: February 26, 1985Date of Patent: February 3, 1987Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Johann Eibl, Otto Schwarz, Fritz Elsinger, Gunter Wober, Anton Philapitsch, Yendra Linnau, Friedrich Dorner, Karl Trambauer, Wolfgang Frechinger
-
Patent number: 4631055Abstract: There is disclosed an arrangement for applying a tissue adhesive based on human or animal proteins to seamlessly or seam-supportingly connect human or animal tissue or organ parts, to seal wounds, stop bleedings and the like. The tissue adhesive is formed in situ by combining solutions of the proteins and of blood-clot-promoting coagulation factors. The arrangement includes a plurality of containers ending in joining pieces for accommodating the components to be applied. A connecting head is attachable to the joining pieces of the containers, which includes a separate conveying channel for each of the components to be applied.Type: GrantFiled: February 26, 1985Date of Patent: December 23, 1986Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Heinz Redl, Georg Habison
-
Patent number: 4608254Abstract: There is disclosed a method for the production of therapeutically administrable plasma derivatives filled in final containers, which are free of prekallikrein activator, hypotensively active constituents and other undesired pharmacologically active substances, of plasma or plasma crude fractions by stepwise enrichment of the plasma proteins, sterile filtration and optionally virus inactivation. In order to make available such plasma fractions that do not develop pharmacologically negative side effects when applied and are producible with an improved activity and yield, C.sub.1 -esterase inhibitor is added during the production process of the plasma derivative, yet prior to its filling into final containers.Type: GrantFiled: March 7, 1984Date of Patent: August 26, 1986Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Anton Philapitsch, Yendra Linnau
-
Patent number: 4600574Abstract: In a method of producing a tissue adhesive based on polysaccharide or on human or animal proteins, a tissue-compatible flat material is impregnated with a solution of fibrinogen and Factor XIII, and lyophilized.Type: GrantFiled: March 21, 1984Date of Patent: July 15, 1986Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Adolf Lindner, Yendra Linnau
-
Patent number: 4522751Abstract: There is described a method for producing a preparation having a high content of Factor VIII (AHF), i.e. with a specific activity of at least 1.5 units of Factor VIII/mg protein, immunoglobulin G (IgG) of from 15 to 30 mg/1000 units of Factor VIII and fibrinogen of from 20 to 40 mg/100 units of Factor VIII. The method consists in that a Factor VIII containing plasma fraction is dissolved in a buffer, the solution is purified from undesired proteins by precipitation and is concentrated, the precipitation of undesired proteins being carried out in the presence of sulfated polysaccharide at a pH of from 6 to 7. After separation of the undesired proteins, a Factor VIII concentrate is precipitated, dissolved and processed into stable form. If desired, an antithrombin III-heparin complex or an antithrombin III-heparinoid complex is added to the solution.Type: GrantFiled: May 18, 1984Date of Patent: June 11, 1985Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Yendra Linnau, Otto Schwarz